Novel substituted pyrazolone derivatives as AMP-activated protein kinase activators to inhibit lipid synthesis and reduce lipid accumulation in ob/ob mice

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a clinical syndrome characterized by hepatic steatosis. NAFLD is closely linked to obesity, insulin resistance and dyslipidemia. AMP-activated protein kinase (AMPK) functions as an energy sensor and plays a central role in regulating lipid metabolism. In this study, we identified a series of novel pyrazolone AMPK activators using a homogeneous time-resolved fluorescence assay (HTRF) based on the AMPKα2β1γ1 complex. Compound 29 (C29) is a candidate compound that directly activated the kinase domain of AMPK with an EC50 value of 2.1–0.2 μmol/L and acted as a non-selective activator of AMPK complexes. Treatment of HepG2 cells with C29 (20, 40 μmol/L) dose-dependently inhibited triglyceride accumulation. Chronic administration of C29 (10, 30 mg/kg every day, po, for 5 weeks) significantly improved lipid metabolism in both the liver and the plasma of ob/ob mice. These results demonstrate that the AMPK activators could be part of a novel treatment approach for NAFLD and associated metabolic disorders.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

References

  1. 1

    Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol 2016; 78: 181–205.

  2. 2

    Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol 2016; 11: 451–96.

  3. 3

    Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686–90.

  4. 4

    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9.

  5. 5

    Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829–38.

  6. 6

    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31.

  7. 7

    Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179–85.

  8. 8

    Heymann F, Tacke F. Immunology in the liver–from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016; 13: 88–110.

  9. 9

    Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774–88.

  10. 10

    Brodosi L, Marchignoli F, Petroni ML, Marchesini G. NASH: a glance at the landscape of pharmacological treatment. Ann Hepatol 2016; 15: 673–81.

  11. 11

    Cassidy S, Syed BA. Nonalcoholic steatohepatitis (NASH) drugs market. Nat Rev Drug Discov 2016; 15: 745–6.

  12. 12

    Hardie DG, Schaffer BE, Brunet A. AMPK: an energy-sensing pathway with multiple inputs and outputs. Trends Cell Biol 2016; 26: 190–201.

  13. 13

    Carling D. AMPK signalling in health and disease. Curr Opin Cell Biol 2017; 45: 31–7.

  14. 14

    Day EA, Ford RJ, Steinberg GR. AMPK as a therapeutic target for treating metabolic diseases. Trends Endocrinol Metab 2017; 28: 545–60.

  15. 15

    Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15–25.

  16. 16

    Quentin T, Kitz J, Steinmetz M, Poppe A, Bar K, Kratzner R. Different expression of the catalytic alpha subunits of the AMP activated protein kinase–an immunohistochemical study in human tissue. Histol Histopathol 2011; 26: 589–96.

  17. 17

    Davies SP, Helps NR, Cohen PT, Hardie DG. 5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett 1995; 377: 421–5.

  18. 18

    Gowans GJ, Hawley SA, Ross FA, Hardie DG. AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab 2013; 18: 556–66.

  19. 19

    Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 2007; 403: 139–48.

  20. 20

    Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006; 3: 403–16.

  21. 21

    Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen ZP, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 2013; 19: 1649–54.

  22. 22

    Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, Steinberg GR. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab 2016; 311: E730–E40.

  23. 23

    Mottillo EP, Desjardins EM, Crane JD, Smith BK, Green AE, Ducommun S, et al. Lack of adipocyte AMPK exacerbates insulin resistance and hepatic steatosis through brown and beige adipose tissue function. Cell Metab 2016; 24: 118–29.

  24. 24

    Woods A, Williams JR, Muckett PJ, Mayer FV, Liljevald M, Bohlooly YM, et al. Liver-specific activation of AMPK prevents steatosis on a high-fructose diet. Cell Rep 2017; 18: 3043–51.

  25. 25

    Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 2007; 282: 32539–48.

  26. 26

    Calabrese MF, Rajamohan F, Harris MS, Caspers NL, Magyar R, Withka JM, et al. Structural basis for AMPK activation: natural and synthetic ligands regulate kinase activity from opposite poles by different molecular mechanisms. Structure 2014; 22: 1161–72.

  27. 27

    Cameron KO, Kung DW, Kalgutkar AS, Kurumbail RG, Miller R, Salatto CT, et al. Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic acid (pf-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy. J Med Chem 2016; 59: 8068–81.

  28. 28

    Cokorinos EC, Delmore J, Reyes AR, Albuquerque B, Kjobsted R, Jorgensen NO, et al. Activation of skeletal muscle AMPK promotes glucose disposal and glucose lowering in non-human primates and mice. Cell Metab 2017; 25: 1147–59 e10.

  29. 29

    Xiao B, Sanders MJ, Carmena D, Bright NJ, Haire LF, Underwood E, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun 2013; 4: 3017.

  30. 30

    Gomez-Galeno JE, Dang Q, Nguyen TH, Boyer SH, Grote MP, Sun Z, et al. A potent and selective AMPK activator that inhibits de novo lipogenesis. ACS Med Chem Lett 2010; 1: 478–82.

  31. 31

    Hunter RW, Foretz M, Bultot L, Fullerton MD, Deak M, Ross FA, et al. Mechanism of action of compound-13: an alpha1-selective small molecule activator of AMPK. Chem Biol 2014; 21: 866–79.

  32. 32

    Myers RW, Guan HP, Ehrhart J, Petrov A, Prahalada S, Tozzo E, et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy. Science 2017; 357: 507–11.

  33. 33

    Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, et al. Co-activation of AMPK and mTORC1 induces cytotoxicity in acute myeloid leukemia. Cell Rep 2015; 11: 1446–57.

  34. 34

    Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett 1994; 353: 33–6.

  35. 35

    Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med 2014; 6: 519–38.

  36. 36

    Li YY, Yu LF, Zhang LN, Qiu BY, Su MB, Wu F, et al. Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice. Toxicol Appl Pharmacol 2013; 273: 325–34.

  37. 37

    Pang T, Zhang ZS, Gu M, Qiu BY, Yu LF, Cao PR, et al. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem 2008; 283: 16051–60.

  38. 38

    Yu LF, Li YY, Su MB, Zhang M, Zhang W, Zhang LN, et al. Development of novel alkene oxindole derivatives as orally efficacious AMP-activated protein kinase activators. ACS Med Chem Lett 2013; 4: 475–80.

  39. 39

    Rajamohan F, Harris MS, Frisbie RK, Hoth LR, Geoghegan KF, Valentine JJ, et al. Escherichia coli expression, purification and characterization of functional full-length recombinant alpha2beta2gamma3 heterotrimeric complex of human AMP-activated protein kinase. Protein Expr Purif 2010; 73: 189–97.

  40. 40

    Treebak JT, Birk JB, Hansen BF, Olsen GS, Wojtaszewski JF. A-769662 activates AMPK beta1-containing complexes but induces glucose uptake through a PI3-kinase-dependent pathway in mouse skeletal muscle. Am J Physiol Cell Physiol 2009; 297: C1041–52.

  41. 41

    Liu J, Chen D, Liu P, He M, Li J, Li J, et al. Discovery, synthesis, and structure-activity relationships of 20(S)-protopanaxadiol (PPD) derivatives as a novel class of AMPKalpha2beta1gamma1 activators. Eur J Med Chem 2014; 79: 340–9.

  42. 42

    Luo C, Long J, Liu J. An improved spectrophotometric method for a more specific and accurate assay of mitochondrial complex III activity. Clin Chim Acta 2008; 395: 38–41.

  43. 43

    Qiu BY, Turner N, Li YY, Gu M, Huang MW, Wu F, et al. High-throughput assay for modulators of mitochondrial membrane potential identifies a novel compound with beneficial effects on db/db mice. Diabetes 2010; 59: 256–65.

  44. 44

    Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006; 574: 41–53.

  45. 45

    Kim M, Hunter RW, Garcia-Menendez L, Gong G, Yang YY, Kolwicz SC Jr, et al. Mutation in the gamma2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. Circ Res 2014; 114: 966–75.

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No 81502910, 81273566 and 81673489), the Shanghai Commission of Science and Technology (No 15ZR1447900 and 14431902800), the Youth Innovation Association of Chinese Academy of Sciences (Mei ZHANG), and the National Key Research and Development Program of China (No 2016YFC1305500).

Author information

Correspondence to Fa-jun Nan or Jing-ya Li.

Electronic supplementary material

Supplementary Materials and methods

Supplementary Figures and Table

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • non-alcoholic fatty liver disease
  • AMP-activated protein kinase
  • AMPK activator
  • homogeneous time-resolved fluorescence
  • metabolic disorders
  • ob/ob micer